Guggenheim Maintains Buy on Verve Therapeutics, Raises Price Target to $24

Benzinga · 04/15 13:52
Guggenheim analyst Etzer Darout maintains Verve Therapeutics (NASDAQ:VERV) with a Buy and raises the price target from $18 to $24.